Heart Health

This news channel includes content on cardiovascular disease prevention, cardiac risk stratification, diagnosis, screening programs, and management of major risk factors that include diabetes, hypertension, diet, life style, cholesterol, obesity, ethnicity and socio-economic disparities.
 

Older LAAO patients, especially women, face a higher risk of complications

Researchers explored data from the National Inpatient Sample, sharing their findings in the American Journal of Cardiology.

Thumbnail

Bariatric surgery associated with lower risk of death and cardiovascular disease

Researchers examined data from 39 different studies, focusing on mortality rates and adverse cardiovascular outcomes. 

There has been fear of a small number of patient who experience myocarditis after COVID vaccination, but a new study found it is safe in patients with prior heart damage. Image courtesy of Banner Health. #COVID19 #COVIDvaccination

COVID-19 vaccines safe for patients with a history of heart damage

“These results provide reassuring data that may encourage patients with a history of myocarditis to get vaccinated against SARS-CoV-2,” one specialist said. 

Nurses caring for a COVID-19 patient in the COVID unit at Banner University Medical Center in Phoenix.

Losartan fails to improve lung injuries in hospitalized COVID-19 patients

Some of the study's findings even raised concerns that losartan could be harming these patients. 

Thumbnail

What routine mammograms can tell us about a woman’s CVD risk

Signs of breast arterial calcification on a patient’s routine mammogram may suggest they face a greater risk of cardiovascular disease.

ACC consensus explains what cardiologists should look for in long COVID-19

The new consensus document provides a framework for understanding, evaluating, and managing some of the key cardiovascular sequelae of COVID-19

Thumbnail

Tofacitinib increases risk of heart issues, cancer among rheumatoid arthritis patients

The FDA and Pfizer worked together to develop this new analysis of more than 4,000 patients. 

Evolocumab

Evolocumab limits adverse cardiovascular outcomes among PCI patients

Data from the FOURIER trial helped clinicians learn more about this popular PCSK9 inhibitor.